RxDoctor Payments Data

Carlton Barnswell, MD

Urology · Elmont, NYNPI 1316921844

Payments from drug & device makers

$124,181in general payments, 2019–2025

Across 518 payments — averaging $239.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$61K
  • Dendreon Pharmaceuticals LLC$28K
  • Ferring Pharmaceuticals AS$10K
  • Astellas Pharma US Inc$7K
  • Ferring International Pharmascience Center US$7K
  • Blue Earth Diagnostics$3K
  • plus $9K from 42 others

What the payments were for

  • Consulting fees$4,8114%
  • Speaking & faculty fees$85,08179%
  • Travel & lodging$4,6304%
  • Food & beverage$12,22511%
  • Education$1,0191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$124,181 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$505,355
Medicare patients
728
Services billed
12,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide164$2,274,708
ErleadaApalutamide122$1,780,232
OrgovyxRelugolix64$172,102
Abiraterone Acetate30$131,614
EligardLeuprolide Acetate88$126,855
MyrbetriqMirabegron105$79,939
XgevaDenosumab13$41,920
Tamsulosin Hcl852$12,472
Tadalafil134$10,766
Tolterodine Tartrate ErTolterodine Tartrate86$6,831
Fesoterodine Fumarate ErFesoterodine Fumarate19$4,709
Trospium Chloride ErTrospium Chloride52$4,561
Oxybutynin Chloride ErOxybutynin Chloride331$4,141
Trospium Chloride86$4,113
Solifenacin Succinate55$3,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$6,775$2,354,646269 claims
Johnson & JohnsonErleada$60,885$1,780,232122 claims
Sumitomo Pharma America, Inc.Orgovyx$383$172,10264 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$2,129$131,61430 claims
Tolmar Pharmaceuticals, Inc.Eligard$164$126,85588 claims
AmgenXgeva$95$41,92013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in Elmont

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →